
K. Gary Barnette
Advertisement
Articles by K. Gary Barnette


Advertisement
Latest Updated Articles
7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 InhibitorPublished: April 18th 2022 | Updated:
8 TiP Randomized, Multicenter, Phase 3 Study to Evaluate the Combination of Enobosarm and Abemaciclib Compared With Estrogen-Blocking Agent for the Second-Line Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Have Previously Received Palbociclib and an Estrogen-Blocking Agent Combination TherapyPublished: April 18th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
3
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5


